Lishengpharma(002393)2022-10-26 16:00Financial Performance - The company's revenue for Q3 2022 was CNY 287,280,219.99, representing a 15.69% increase year-over-year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 40,669,839.84, an increase of 11.53% compared to the same period last year[4] - The basic earnings per share for Q3 2022 was CNY 0.22, reflecting a 10.00% increase year-over-year[4] - Total operating revenue for the current period reached ¥902,020,309.45, an increase of 7.93% compared to ¥835,659,085.18 in the previous period[22] - Operating profit for the current period was ¥138,981,098.89, representing an increase of 16.19% from ¥119,607,409.54 in the previous period[23] - Net profit for the current period was ¥112,623,728.95, a rise of 15.2% compared to ¥97,716,985.27 in the previous period[23] - The company reported a total comprehensive income of ¥112,623,728.95 for the current period, compared to ¥97,716,985.27 in the previous period, an increase of 15.2%[24] - Basic earnings per share for the current period was ¥0.62, compared to ¥0.54 in the previous period, reflecting an increase of 14.81%[24] Assets and Liabilities - Total assets as of September 30, 2022, amounted to CNY 5,412,250,132.71, a 4.26% increase from the end of the previous year[4] - Total current assets as of September 30, 2022, amount to ¥2,239,744,876.65, a decrease from ¥2,356,429,105.55 at the beginning of the year[19] - Total assets as of September 30, 2022, are ¥5,412,250,132.71, compared to ¥5,190,932,494.57 at the beginning of the year[20] - Total liabilities as of September 30, 2022, amount to ¥940,648,973.80, an increase from ¥780,423,684.69 at the beginning of the year[20] - The company has a total equity of ¥4,471,601,158.91 as of September 30, 2022, compared to ¥4,410,508,809.88 at the beginning of the year[20] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 198,170,319.93, a significant increase of 73.12%[4] - Cash flow from operating activities generated a net amount of ¥198,170,319.93, compared to ¥114,469,864.37 in the previous period, marking a significant increase of 73.2%[27] - Cash inflow from investment activities totaled ¥77,939,911.69, compared to ¥9,759,403.81 in the previous period, showing a substantial increase[27] - Cash outflow from investment activities was ¥400,676,221.85, up from ¥137,751,103.87, indicating a rise of 190.5%[27] - Cash flow from financing activities showed a net outflow of CNY 54,855,788.17, compared to a net outflow of CNY 8,879,688.32 in the previous period[28] - The net increase in cash and cash equivalents for the quarter was a decrease of CNY 179,421,778.40, compared to a decrease of CNY 22,401,524.01 in the same period last year[28] - The ending balance of cash and cash equivalents was CNY 1,448,245,422.50, down from CNY 1,503,292,310.82 at the end of the previous period[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,620[15] - The largest shareholder, Tianjin Jinhao Pharmaceutical Co., Ltd., holds 51.36% of shares, totaling 93,710,608 shares[15] Investments - The company reported a 100% increase in other debt investments to CNY 200,000,000.00, attributed to investments in financial products[9] - The company reported a 100% increase in cash received from investment activities, amounting to CNY 70,202,957.77, due to the recovery of maturing financial products[11]